NEOVACS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0315 EUR | -6.80% |
|
-28.57% | -98.42% |
| 06-17 | Neovacs: collaboration agreement with CNRS | CF |
| 06-10 | Neovacs: presents results from vaccine candidates | CF |
| Sales 2022 | 1.11K 1.19K 94K | Sales 2023 | 533K 572K 45.09M | Capitalization | 278 298.17 23.5K |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.22M -254M | Net income 2023 | -8M -8.58M -676M | EV / Sales 2022 | - |
| Net cash position 2022 | 5.55M 5.96M 470M | Net cash position 2023 | 237K 254K 19.99M | EV / Sales 2023 | -0.44 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | 22 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0.12% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -6.80% | ||
| 1 week | -28.57% | ||
| Current month | -78.12% | ||
| 1 month | -81.47% | ||
| 3 months | -96.42% | ||
| 6 months | -98.42% | ||
| Current year | -98.42% |
1 week
0.03
0.06
1 month
0.030.42
Current year
0.033.20
1 year
0.039 250.00
3 years
0.031 000 000.00
5 years
0.031 000 000.00
10 years
0.031 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | - | 30/09/20 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19/02/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 85 | 27/05/03 | |
Daniel Zagury
FOU | Founder | - | 15/04/93 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 0.0315 | -6.80% | 696 525 |
| 19/06/24 | 0.0338 | -3.43% | 313,500 |
| 18/06/24 | 0.035 | -0.57% | 625,577 |
| 17/06/24 | 0.0352 | -14.15% | 1,223,690 |
| 14/06/24 | 0.041 | -7.03% | 451,098 |
Real-time Euronext Paris, June 20, 2024 at 12:52 pm
More quotes
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
| 1st Jan change | Capi. | |
|---|---|---|
| -98.42% | 144K | |
| +34.01% | 51.07B | |
| +34.80% | 38.61B | |
| -8.02% | 38.78B | |
| -8.98% | 27.32B | |
| +12.56% | 26.35B | |
| -19.62% | 19.46B | |
| +39.18% | 13.58B | |
| +31.47% | 12.46B | |
| -3.40% | 11.75B |
- Stock Market
- Equities
- ALNEV Stock
